

Assisting Clients with Quitting – How to Talk the Talk for Successful Tobacco Cessation (Part II)

Presented by Frank Vitale, MA

*National Director, Pharmacy Partnership for Tobacco Cessation
Clinical Assistant Professor, Purdue College of Pharmacy*

To access closed captioning:

<https://www.streamtext.net/player?event=AssistingClientswithQuittingTobaccoPart2>



National Behavioral Health Network
For Tobacco & Cancer Control

UCSF Smoking Cessation
Leadership Center

National Center of Excellence for
Tobacco-Free Recovery

Monday, March 09, 2020, 2:00 PM EDT

**NATIONAL COUNCIL
FOR BEHAVIORAL HEALTH**
STATE ASSOCIATIONS OF ADDICTION SERVICES
Stronger Together.



Welcome!



Samara Tahmid

Project Coordinator of Practice Improvement,
National Council for Behavioral Health



Frank Vitale, MA

National Director, Pharmacy Partnership for Tobacco Cessation
Clinical Assistant Professor, Purdue College of Pharmacy



Housekeeping

- Webinar is being recorded. All participants placed in “listen-only” mode.
- For audio access, participants can either dial into the conference line or listen through your computer speakers.
- Submit questions by typing them into the chatbox.
- Presentation slides, handouts and recording will be posted here:
 - <https://www.bhthechange.org/resources/resource-type/archived-webinars/>



National Behavioral Health Network

For Tobacco & Cancer Control

- Jointly funded by CDC's *Office on Smoking & Health & Division of Cancer Prevention & Control*
- Provides resources and tools to help organizations reduce tobacco use and cancer among people with mental illness and addictions
- 1 of 8 CDC National Networks to eliminate cancer and tobacco disparities in priority populations

Visit www.BHtheChange.org and
Join Today!

Free Access to...

Toolkits, training opportunities, virtual communities and other resources

Webinars & Presentations

State Strategy Sessions

Communities of Practice



#BHtheChange





AUSTIN | TEXAS | APRIL 5 - 7

NATCON | 20

Kaleidoscope

Registration is now open!

National Behavioral Health Network 2019 Annual Membership Survey:

<https://is.gd/NBHN2019MembershipSurvey>

Disclosures

This UCSF CME activity was planned and developed to uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

The following faculty speakers, moderators, and planning committee members have disclosed they have no financial interest/arrangement or affiliation with any commercial companies who have provided products or services relating to their presentation(s) or commercial support for this continuing medical education activity:

Frank Vitale, MA, Taslim van Hattum, LCSW, MPH, Samara Tahmid, Dana Lange, Christine Cheng, Jennifer Matekuare, Catherine Saucedo, and Steve Schroeder, MD

Learning Objectives

- Identify and implement evidence-based strategies to engage behavioral health populations with high rates of tobacco use.
- Enhance motivational interviewing techniques to best engage clients in tobacco cessation attempts.
- Increase knowledge of FDA approved NRTs and other pharmacological supports to best support your clinicians and clients.

CME/CEU Statement

Accreditation:

The University of California, San Francisco (UCSF) School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UCSF designates this live activity for a maximum of *1.0 AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the webinar activity.

Advance Practice Registered Nurses and Registered Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts *AMA PRA Category 1 Credit™* issued by organizations accredited by the ACCME.

Physician Assistants: The National Commission on Certification of Physician Assistants (NCCPA) states that the *AMA PRA Category 1 Credit™* are acceptable for continuing medical education requirements for recertification.

California Pharmacists: The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for *AMA PRA category 1 Credit™*. If you are a pharmacist in another state, you should check with your state board for approval of this credit.

California Marriage & Family Therapists: University of California, San Francisco School of Medicine (UCSF) is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for behavioral health providers. UCSF maintains responsibility for this program/course and its content.

Respiratory Therapists: This program has been approved for a maximum of 1.0 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425 N MacArthur Blvd. Suite 100 Irving, TX 75063. Course # 183137000.

Course meets the qualifications for 1.0 hour of continuing education credit for **LMFTs, LCSWs, LPCCs, and/or LEPs** as required by the California Board of Behavioral Sciences. Provider # 64239.



ASSISTING CLIENTS WITH QUITTING Part II: Optimization of Nicotine Replacement Therapy & Pharmacological Supports

Frank Vitale, MA

National Director, Pharmacy Partnership for Tobacco Cessation
Clinical Assistant Professor, Purdue College of Pharmacy



DRUG INTERACTIONS with SMOKING



PHARMACOKINETIC DRUG INTERACTIONS with SMOKING

Drugs that may have a *decreased effect* due to induction of CYP1A2:

- Bendamustine
- Caffeine
- Clozapine
- Erlotinib
- Fluvoxamine
- Irinotecan (clearance increased and systemic exposure decreased, due to increased glucuronidation of its active metabolite)
- Haloperidol
- Olanzapine
- Riociguat
- Ropinirole
- Tacrine
- Tasimelteon
- Theophylline

Smoking cessation will reverse these effects.



DRUG INTERACTION: TOBACCO SMOKE and CAFFEINE

- Constituents in tobacco smoke induce CYP1A2 enzymes, which metabolize caffeine
 - Caffeine levels increase ~56% upon quitting
- Nicotine withdrawal effects might be enhanced by increased caffeine levels
- Decrease caffeine intake by 50% when quitting; no caffeine after 1PM for individuals with a typical bedtime



PHARMACODYNAMIC DRUG INTERACTIONS with SMOKING

Smokers who use combined hormonal contraceptives have an increased risk of serious cardiovascular adverse effects:

- Stroke
- Myocardial infarction
- Thromboembolism



This interaction **does not** decrease the efficacy of hormonal contraceptives.

Women who are 35 years of age or older AND smoke at least 15 cigarettes per day are at significantly elevated risk.



DRUG INTERACTIONS with SMOKING: SUMMARY

Clinicians should be aware of their patients' smoking status:

- Clinically significant interactions result from the combustion products of tobacco smoke, not from nicotine.
- Constituents in tobacco smoke (e.g., polycyclic aromatic hydrocarbons; PAHs) may enhance the metabolism of other drugs, resulting in an altered pharmacologic response.
- Changes in smoking status might alter the clinical response to the treatment of a wide variety of conditions.
- Drug interactions with smoking should be considered when patients start smoking, quit smoking, or markedly alter their levels of smoking.




MEDICATIONS for CESSATION



PHARMACOTHERAPY

“Clinicians should encourage all patients attempting to quit to use effective medications for tobacco dependence treatment, except where contraindicated or for specific populations* for which there is insufficient evidence of effectiveness.”



* Includes pregnant women, smokeless tobacco users, light smokers, and adolescents.

Medications significantly improve success rates.

Fiore et al. (2008). *Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline*. Rockville, MD: USDHHS, PHS, May 2008.



FDA-APPROVED MEDICATIONS for CESSATION

Nicotine polacrilex gum*

- Nicorette (OTC)
- Generic nicotine gum (OTC)

Nicotine lozenge*

- Nicorette (OTC)
- Generic nicotine lozenge (OTC)

Nicotine transdermal patch*

- NicoDerm CQ (OTC)
- Generic nicotine patches (OTC)

Nicotine inhaler *

- Nicotrol (Rx)

Nicotine nasal spray *

- Nicotrol NS (Rx)

Bupropion SR

- Zyban (Rx)
- Generic bupropion SR (Rx)

Varenicline

- Chantix (Rx)

* Nicotine replacement therapy (NRT) products.




NICOTINE REPLACEMENT THERAPY (NRT) RATIONALE for USE

- Reduces physical withdrawal from nicotine
- Eliminates the immediate, reinforcing effects of nicotine that is rapidly absorbed via tobacco smoke
- Allows patient to focus on behavioral and psychological aspects of tobacco cessation

NRT products approximately doubles quit rates.



PLASMA NICOTINE CONCENTRATIONS for NICOTINE-CONTAINING PRODUCTS





NRT: PRECAUTIONS

- Patients with underlying cardiovascular disease
 - Recent myocardial infarction (within past 2 weeks)
 - Serious arrhythmias
 - Serious or worsening angina

NRT products may be appropriate for these patients if they are under medical supervision.



NICOTINE GUM

Nicorette; generics

- Resin complex
 - Nicotine
 - Polacrillin
- Sugar-free chewing gum base
- Contains buffering agents to enhance buccal absorption of nicotine
- Available: 2 mg, 4 mg; original, cinnamon, fruit, and mint (various) flavors





NICOTINE LOZENGE

Nicorette Lozenge and Nicorette Mini Lozenge; generics

- Nicotine polacrilex formulation
 - Delivers ~25% more nicotine than equivalent gum dose
- Sugar-free mint, cherry flavors
- Contains buffering agents to enhance buccal absorption of nicotine
- Available: 2 mg, 4 mg





NICOTINE GUM & LOZENGE: DOSING

Dose based on the “time to first cigarette” (TTFC)
as an indicator of nicotine dependence

Use the 2 mg gum/lozenge:

If first cigarette of the day is
smoked more than 30 minutes
after waking

Use the 4 mg gum/lozenge:

If first cigarette of the day is
smoked within 30 minutes of
waking





NICOTINE GUM & LOZENGE: DOSING (cont'd)


Recommended Usage Schedule

Weeks 1–6	Weeks 7–9	Weeks 10–12
1 piece q 1–2 h	1 piece q 2–4 h	1 piece q 4–8 h

**Do not use more than 24 pieces of GUM
or 20 LOZENGES per day.**



NICOTINE GUM: DIRECTIONS FOR USE





NICOTINE LOZENGE: DIRECTIONS for USE

- Place in mouth and allow to dissolve slowly (nicotine release may cause warm, tingling sensation)
- Do not chew or swallow
- Occasionally rotate to different areas of the mouth
- Lozenges will dissolve completely in about 20–30 minutes



NICOTINE GUM/LOZENGE: ADDITIONAL PATIENT EDUCATION

- To improve chances of quitting, use at least nine pieces daily during the first 6 weeks
- The gum/lozenge will *not* provide the same rapid satisfaction that smoking provides
- The effectiveness of the nicotine gum/lozenge may be reduced by some foods and beverages:
 - Coffee
 - Wine
 - Juices
 - Soft drinks

Do NOT eat or drink for 15 minutes BEFORE or while using the nicotine gum or lozenge.



NICOTINE GUM/LOZENGE: ADD'L PATIENT EDUCATION (cont'd)

- Chewing the lozenge or using incorrect gum chewing technique can cause excessive and rapid release of nicotine, resulting in:
 - Lightheadedness/dizziness
 - Nausea and vomiting
 - Hiccups
 - Irritation of throat and mouth



NICOTINE GUM/LOZENGE: ADD'L PATIENT EDUCATION (cont'd)

- Adverse effects of nicotine gum and lozenge:
 - Mouth and throat irritation
 - Hiccups
 - Gastrointestinal complaints (dyspepsia, nausea)
- Adverse effects associated with nicotine gum:
 - Jaw muscle ache
 - May stick to dental work



NICOTINE GUM/LOZENGE: SUMMARY

ADVANTAGES

- Might serve as an oral substitute for tobacco
- Might delay weight gain
- Can be titrated to manage withdrawal symptoms
- Can be used in combination with other agents to manage situational urges
- Relatively inexpensive

DISADVANTAGES

- Need for frequent dosing can compromise adherence
- Gastrointestinal adverse effects (nausea, hiccups, and dyspepsia) may be bothersome
- Specific to nicotine gum:
 - Might be problematic for patients with significant dental work
 - Proper chewing technique is necessary for effectiveness and to minimize adverse effects
 - Chewing might not be acceptable or desirable for some patients



TRANSDERMAL NICOTINE PATCH

NicoDerm CQ; generic

- Continuous (24-hour) nicotine delivery system
- Nicotine is well absorbed across the skin
- Transdermal delivery to systemic circulation avoids hepatic first-pass metabolism
- Plasma nicotine levels are lower and fluctuate less than with smoking






TRANSDERMAL NICOTINE PATCH: DOSING

Product	Light Smoker	Heavy Smoker
NicoDerm CQ	≤10 cigarettes/day Step 2 (14 mg x 6 weeks) Step 3 (7 mg x 2 weeks)	> 10 cigarettes/day Step 1 (21 mg x 6 weeks) Step 2 (14 mg x 2 weeks) Step 3 (7 mg x 2 weeks)
Generic	≤10 cigarettes/day Step 2 (14 mg x 6 weeks) Step 3 (7 mg x 2 weeks)	> 10 cigarettes/day Step 1 (21 mg x 4 weeks) Step 2 (14 mg x 2 weeks) Step 3 (7 mg x 2 weeks)



TRANSDERMAL NICOTINE PATCH: DIRECTIONS for USE

- Choose an area of skin on the upper body or upper outer part of the arm
- Make sure skin is clean, dry, hairless, and not irritated
- Apply patch to different area each day
- Do not use same area again for at least 1 week





TRANSDERMAL NICOTINE PATCH: ADDITIONAL PATIENT EDUCATION

- Water will not harm the nicotine patch if it is applied correctly; patients may bathe, swim, shower, or exercise while wearing the patch
- Do *not* cut patches to adjust dose
 - Can unpredictably effect nicotine delivery
 - Patch may be less effective
- Keep new and used patches out of the reach of children and pets
- Remove patch before MRI procedures





TRANSDERMAL NICOTINE PATCH: ADD'L PATIENT EDUCATION (cont'd)

Common adverse effects include:

- Irritation at the patch application site (generally within the first hour)
 - Mild itching
 - Burning
 - Tingling
- Sleep disturbances
 - Abnormal or vivid dreams
 - Insomnia



TRANSDERMAL NICOTINE PATCH: SUMMARY

ADVANTAGES

- Once-daily dosing associated with fewer adherence problems
- Of all NRT products, its use is least obvious to others
- Can be used in combination with other agents; delivers consistent nicotine levels over 24 hrs
- Relatively inexpensive

DISADVANTAGES


- When used as monotherapy, cannot be titrated to acutely manage withdrawal symptoms
- Not recommended for use by patients with dermatologic conditions (e.g., psoriasis, eczema, atopic dermatitis)



NICOTINE INHALER

Nicotrol Inhaler

- Nicotine inhalation system consists of:
 - Mouthpiece
 - Cartridge with porous plug containing 10 mg nicotine and 1 mg menthol
- Delivers 4 mg nicotine vapor, absorbed across buccal mucosa





NICOTINE NASAL SPRAY

Nicotrol NS


- Aqueous solution of nicotine in a 10-ml spray bottle
- Each metered dose actuation delivers
 - 50 mcL spray
 - 0.5 mg nicotine
- ~100 doses/bottle
- Rapid absorption across nasal mucosa





BUPROPION SR: Zyban; generics

- Non-nicotine cessation aid
- Mechanism of action: atypical antidepressant
 - Dopamine
 - Norepinephrine
- Clinical effects
 - ↓ craving for cigarettes
 - ↓ symptoms of nicotine withdrawal
- Contraindication: Seizure disorder





BUPROPION: WARNINGS and PRECAUTIONS (cont'd)

- Neuropsychiatric symptoms and suicide risk
 - Changes in mood (including depression and mania)
 - Psychosis/hallucinations/paranoia/delusions
 - Homicidal ideation
 - Aggression/hostility/anxiety/panic
 - Suicidal ideation, suicide attempt, completed suicide

**FDA
boxed
warning
removed
Dec 2016**

Advise patients to stop taking bupropion SR and contact a health care provider immediately if symptoms such as agitation, depressed mood, or changes in behavior or thinking that are not typical are observed or if the patient develops suicidal ideation or suicidal behavior.



BUPROPION: ADVERSE EFFECTS

Common adverse effects include the following:

- Insomnia (avoid bedtime dosing)
- Dry mouth
- Nausea

Less common but reported effects:

- Anxiety/difficulty concentrating
- Constipation
- Tremor
- Skin rash



BUPROPION SR: SUMMARY

ADVANTAGES

- Oral dosing is simple and associated with fewer adherence problems
- Might delay weight gain
- Bupropion might be beneficial in patients with depression
- Can be used in combination with NRT agents
- Relatively inexpensive (generic formulations)

DISADVANTAGES

- Seizure risk is increased
- Several contraindications and precautions preclude use in some patients
- Patients should be monitored for neuropsychiatric symptoms



VARENICLINE

Chantix

- Nonnicotine cessation aid
- Partial nicotinic receptor agonist
- Oral formulation





VARENICLINE: MECHANISM of ACTION

- Binds with high affinity and selectivity at $\alpha_4\beta_2$ neuronal nicotinic acetylcholine receptors
 - Stimulates low-level agonist activity
 - Competitively inhibits binding of nicotine
- Clinical effects
 - ↓ symptoms of nicotine withdrawal
 - Blocks dopaminergic stimulation responsible for reinforcement & reward associated with smoking



VARENICLINE: WARNINGS and PRECAUTIONS

- Neuropsychiatric symptoms and suicide risk
 - Changes in mood (including depression and mania)
 - Psychosis/hallucinations/paranoia/delusions
 - Homicidal ideation
 - Aggression/hostility/anxiety/panic
 - Suicidal ideation, suicide attempt, completed suicide

**FDA
boxed
warning
removed
Dec 2016**

Advise patients to stop taking varenicline and contact a health care provider immediately if symptoms such as agitation, depressed mood, or changes in behavior or thinking that are not typical are observed or if the patient develops suicidal ideation or suicidal behavior.



VARENICLINE: STANDARD DOSING

Patients should begin therapy 1 week PRIOR to their quit date. The dose is gradually increased to minimize treatment-related nausea and insomnia.

	Treatment Day	Dose
<i>Initial dose titration</i>	Day 1 to day 3	 0.5 mg qd
	Day 4 to day 7	  0.5 mg bid
	Day 8 to end of treatment*	  1 mg bid

* Up to 12 weeks



VARENICLINE: ADVERSE EFFECTS

Common adverse effects include the following:

- Nausea
- Insomnia
- Abnormal dreams
- Headache

Less common adverse effects:

- Gastrointestinal (flatulence, constipation)
- Taste alteration



VARENICLINE: ADDITIONAL PATIENT EDUCATION

- Doses should be taken after eating, with a full glass of water
- Nausea and insomnia are usually temporary side effects
 - If symptoms persist, notify your health care provider
- May experience vivid, unusual or strange dreams during treatment
- Use caution driving, drinking alcohol, and operating machinery until effects of quitting smoking with varenicline are known



VARENICLINE: SUMMARY

ADVANTAGES

- Oral dosing is simple and associated with fewer adherence problems
- Offers a different mechanism of action for persons who have failed other agents
- Most effective agent for cessation when used as monotherapy

DISADVANTAGES

- Cost of treatment
- Patients should be monitored for potential neuropsychiatric symptoms



COMBINATION PHARMACOTHERAPY

Regimens with enough evidence to be 'recommended' first-line

■ **Combination NRT**

Long-acting formulation (patch)

- Produces relatively constant levels of nicotine

PLUS

Short-acting formulation (gum, inhaler, lozenge, nasal spray)

- Allows for acute dose titration as needed for nicotine withdrawal symptoms

■ **Bupropion SR + Nicotine Patch**



COMBINATION NRT: TREATMENT REGIMENS

- **Nicotine patch**
Dose: 21 mg/day x 4–6 wks → 14 mg/day x 2 wks → 7 mg/day x 2 wks
PLUS
- **Nicotine gum or lozenge** (2 mg/4 mg; based on TTFC)
Dose: Use 1 piece q 1–2 hours as needed (use at least 4-5/day)
OR
- **Nicotine inhaler** (10 mg cartridge; delivers 4 mg nicotine vapor)
Dose: Use 1 cartridge q 1–2 hours as needed
OR
- **Nicotine nasal spray** (0.5 mg/spray)
Dose: Use 1 spray in each nostril q 1–2 hours as needed



“Drugs don’t work...

...in patients who
don’t take them.”

C. Everett Koop, M.D., former U.S. Surgeon General



**Medication adherence should be
addressed at each encounter.**



SUMMARY

- To maximize success, interventions should include behavioral counseling and one or more medications
- Encourage the use of effective medications by all patients attempting to quit smoking
 - Exceptions include medical contraindications or specific populations for which there is insufficient evidence of effectiveness
- First-line medications that reliably increase long-term smoking cessation rates include:
 - Bupropion SR
 - Nicotine replacement therapy (as monotherapy or combination therapy)
 - Varenicline
- Varenicline and combination NRT approaches demonstrate the highest level of efficacy



Contact Information:

Frank Vitale, M.A.

National Director,

Pharmacy Partnership for Tobacco Cessation

vitalefm@msn.com

412 481-7767



References

- Motivational Interviewing: Preparing People for Change William R. Miller and Stephen Rollnick, The Guilford Press 2002
- Motivational Interviewing in HealthCare William R. Miller/Stephen Rollnick Guilford Press 2008
- <https://rxforchange.ucsf.edu/>



Comments and Questions?





Thank you for joining us!

*Please be sure to complete the brief post-webinar
evaluation.*



National Behavioral Health Network
For Tobacco & Cancer Control

Visit BHtheChange.org and Join Today!